{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,8]],"date-time":"2026-11-08T03:53:56Z","timestamp":1794110036552,"version":"4.8.0"},"reference-count":37,"publisher":"American Society of Hematology","issue":"8","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,4,28]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>The International Myeloma Society (IMS) and the International Myeloma Working Group (IMWG) recently published a new consensus genomic staging (CGS) for defining high-risk (HR) newly diagnosed multiple myeloma (NDMM), intended to provide consistency in clinical trial reporting and for use in designing enrichment clinical trials focused on the HR subset. The HR definition is the first to include TP53 mutations and considers the co-occurrence of immunoglobulin H translocations with chromosome 1 aberrations. Given that limited data from the anti-CD38 monoclonal antibody-based quadruplet induction regimens were available for consensus consideration, here, we demonstrate that the new HR definition also predicts clinical outcomes in this setting. The patient population comprised 503 patients with NDMM treated with daratumumab-based quadruplet induction therapy at Memorial Sloan Kettering Cancer Center, with a median follow-up time of 2.2 years (maximum, 7.9 years). The CGS criteria defined 31% of NDMM cases as HR, better delineating patients at intermediate risk by preexisting prognostic scores. The CGS did not predict early minimal residual disease (MRD) status, with MRD negativity occurring at the same rate in patients with HR and standard-risk (SR) NDMM. However, the CGS did predict progression-free survival (PFS), with a median of 2.6 years in HR compared with not reached in SR (P&amp;lt; .0001). CGS risk remained predictive of PFS even in the setting of MRD negativity after autologous stem cell transplantation. We conclude that although the IMS-IMWG CGS is ideal for standardizing NDMM trial design, any MRD-guided trial design should also consider genomic risk.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2025018537","type":"journal-article","created":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T22:04:56Z","timestamp":1771365896000},"page":"2616-2625","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":8,"title":["IMS-IMWG 2025 consensus genomic staging predicts outcomes with daratumumab-based quadruplet regimens for NDMM"],"prefix":"10.1182","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7873-4854","authenticated-orcid":false,"given":"Kylee H.","family":"Maclachlan","sequence":"first","affiliation":[{"name":"1Myeloma Service, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7922-2594","authenticated-orcid":false,"given":"Carlyn R.","family":"Tan","sequence":"additional","affiliation":[{"name":"1Myeloma Service, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tala","family":"Shekarkhand","sequence":"additional","affiliation":[{"name":"1Myeloma Service, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colin","family":"Rueda","sequence":"additional","affiliation":[{"name":"1Myeloma Service, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2178-8493","authenticated-orcid":false,"given":"Andriy","family":"Derkach","sequence":"additional","affiliation":[{"name":"2Department of Epidemiology & Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamza","family":"Hashmi","sequence":"additional","affiliation":[{"name":"1Myeloma Service, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hani","family":"Hassoun","sequence":"additional","affiliation":[{"name":"1Myeloma Service, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8419-1091","authenticated-orcid":false,"given":"Urvi A.","family":"Shah","sequence":"additional","affiliation":[{"name":"1Myeloma Service, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9045-6495","authenticated-orcid":false,"given":"Malin","family":"Hultcrantz","sequence":"additional","affiliation":[{"name":"1Myeloma Service, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9321-702X","authenticated-orcid":false,"given":"Alexander M.","family":"Lesokhin","sequence":"additional","affiliation":[{"name":"1Myeloma Service, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sham","family":"Mailankody","sequence":"additional","affiliation":[{"name":"1Myeloma Service, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5017-1620","authenticated-orcid":false,"given":"Francesco","family":"Maura","sequence":"additional","affiliation":[{"name":"1Myeloma Service, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maximillian","family":"Merz","sequence":"additional","affiliation":[{"name":"1Myeloma Service, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2945-9320","authenticated-orcid":false,"given":"Ross","family":"Firestone","sequence":"additional","affiliation":[{"name":"1Myeloma Service, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric M.","family":"Jurgens","sequence":"additional","affiliation":[{"name":"1Myeloma Service, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5534-5570","authenticated-orcid":false,"given":"Kevin C.","family":"Miller","sequence":"additional","affiliation":[{"name":"3Adult Bone Marrow Transplantation Service, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sridevi","family":"Rajeeve","sequence":"additional","affiliation":[{"name":"1Myeloma Service, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1944-5053","authenticated-orcid":false,"given":"Sergio","family":"Giralt","sequence":"additional","affiliation":[{"name":"3Adult Bone Marrow Transplantation Service, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9977-0456","authenticated-orcid":false,"given":"Gunjan L.","family":"Shah","sequence":"additional","affiliation":[{"name":"3Adult Bone Marrow Transplantation Service, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Scordo","sequence":"additional","affiliation":[{"name":"3Adult Bone Marrow Transplantation Service, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3152-1189","authenticated-orcid":false,"given":"Heather J.","family":"Landau","sequence":"additional","affiliation":[{"name":"3Adult Bone Marrow Transplantation Service, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanming","family":"Zhang","sequence":"additional","affiliation":[{"name":"4Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Cimera","sequence":"additional","affiliation":[{"name":"4Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria E.","family":"Arcila","sequence":"additional","affiliation":[{"name":"4Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5538-4318","authenticated-orcid":false,"given":"Neha","family":"Korde","sequence":"additional","affiliation":[{"name":"1Myeloma Service, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saad Z.","family":"Usmani","sequence":"additional","affiliation":[{"name":"1Myeloma Service, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2026,4,15]]},"reference":[{"issue":"3","key":"2026042809465886900_bib1","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1002\/1097-0142(197509)36:3<842::AID-CNCR2820360303>3.0.CO;2-U","article-title":"A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival","volume":"36","author":"Durie","year":"1975","journal-title":"Cancer"},{"issue":"15","key":"2026042809465886900_bib2","doi-asserted-by":"crossref","first-page":"3412","DOI":"10.1200\/JCO.2005.04.242","article-title":"International staging system for multiple myeloma","volume":"23","author":"Greipp","year":"2005","journal-title":"J Clin Oncol"},{"issue":"8","key":"2026042809465886900_bib3","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1182\/blood.2020005288","article-title":"Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial","volume":"136","author":"Voorhees","year":"2020","journal-title":"Blood"},{"issue":"suppl 15","key":"2026042809465886900_bib4","doi-asserted-by":"crossref","first-page":"8002","DOI":"10.1200\/JCO.2019.37.15_suppl.8002","article-title":"Efficacy of carfilzomib lenalidomide dexamethasone (KRd) with or without transplantation in newly diagnosed myeloma according to risk status: results from the FORTE trial","volume":"37","author":"Gay","year":"2019","journal-title":"J Clin Oncol"},{"issue":"suppl 1","key":"2026042809465886900_bib5","first-page":"860-860","article-title":"Daratumumab, carfilzomib, lenalidomide and dexamethasone (Dara-KRd) induction, autologous transplantation and post-transplant, response-adapted, measurable residual disease (MRD)-based Dara-Krd consolidation in patients with newly diagnosed multiple myeloma (NDMM)","volume":"134","author":"Costa","year":"2019","journal-title":"Blood"},{"issue":"1","key":"2026042809465886900_bib6","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1038\/s41408-023-00797-8","article-title":"Isatuximab, carfilzomib, and dexamethasone in patients with relapsed multiple myeloma: updated results from IKEMA, a randomized Phase 3 study","volume":"13","author":"Martin","year":"2023","journal-title":"Blood Cancer J"},{"issue":"4","key":"2026042809465886900_bib7","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1038\/s41591-024-03485-7","article-title":"Daratumumab plus bortezomib, lenalidomide and dexamethasone for transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma: the randomized phase 3 CEPHEUS trial","volume":"31","author":"Usmani","year":"2025","journal-title":"Nat Med"},{"issue":"26","key":"2026042809465886900_bib8","doi-asserted-by":"crossref","first-page":"2863","DOI":"10.1200\/JCO.2015.61.2267","article-title":"Revised international staging system for multiple myeloma: a report from International Myeloma Working Group","volume":"33","author":"Palumbo","year":"2015","journal-title":"J Clin Oncol"},{"issue":"14","key":"2026042809465886900_bib9","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1056\/NEJMoa1611750","article-title":"Lenalidomide, bortezomib, and dexamethasone with transplantation for myeloma","volume":"376","author":"Attal","year":"2017","journal-title":"N Engl J Med"},{"issue":"1","key":"2026042809465886900_bib10","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1038\/s41375-018-0196-8","article-title":"A high-risk, double-hit, group of newly diagnosed myeloma identified by genomic analysis","volume":"33","author":"Walker","year":"2019","journal-title":"Leukemia"},{"issue":"25","key":"2026042809465886900_bib11","doi-asserted-by":"crossref","first-page":"2901","DOI":"10.1200\/JCO.21.01935","article-title":"Daratumumab, carfilzomib, lenalidomide, and dexamethasone with minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma","volume":"40","author":"Costa","year":"2022","journal-title":"J Clin Oncol"},{"issue":"1","key":"2026042809465886900_bib12","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/S1470-2045(22)00693-3","article-title":"Carfilzomib induction, consolidation, and maintenance with or without autologous stem-cell transplantation in patients with newly diagnosed multiple myeloma: pre-planned cytogenetic subgroup analysis of the randomised, phase 2 FORTE trial","volume":"24","author":"Mina","year":"2023","journal-title":"Lancet Oncol"},{"issue":"29","key":"2026042809465886900_bib13","doi-asserted-by":"crossref","first-page":"3406","DOI":"10.1200\/JCO.21.02614","article-title":"Second revision of the International Staging System (R2-ISS) for overall survival in multiple myeloma: a European Myeloma Network (EMN) report within the HARMONY Project","volume":"40","author":"D'Agostino","year":"2022","journal-title":"J Clin Oncol"},{"issue":"1","key":"2026042809465886900_bib14","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1038\/s41408-024-01149-w","article-title":"Allocation and validation of the second revision of the International Staging System in the ICARIA-MM and IKEMA studies","volume":"14","author":"Richardson","year":"2024","journal-title":"Blood Cancer J"},{"issue":"24","key":"2026042809465886900_bib15","doi-asserted-by":"crossref","first-page":"2739","DOI":"10.1200\/JCO-24-01893","article-title":"International Myeloma Society\/International Myeloma Working Group consensus recommendations on the definition of high-risk multiple myeloma","volume":"43","author":"Avet-Loiseau","year":"2025","journal-title":"J Clin Oncol"},{"issue":"10192","key":"2026042809465886900_bib16","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(19)31240-1","article-title":"Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study","volume":"394","author":"Moreau","year":"2019","journal-title":"Lancet"},{"issue":"12","key":"2026042809465886900_bib17","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1038\/s43018-023-00657-1","article-title":"Genomic and immune signatures predict clinical outcome in newly diagnosed multiple myeloma treated with immunotherapy regimens","volume":"4","author":"Maura","year":"2023","journal-title":"Nat Cancer"},{"issue":"6","key":"2026042809465886900_bib18","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1001\/jamaoncol.2021.0611","article-title":"Safety and effectiveness of weekly carfilzomib, lenalidomide, dexamethasone, and daratumumab combination therapy for patients with newly diagnosed multiple myeloma: the MANHATTAN nonrandomized clinical trial","volume":"7","author":"Landgren","year":"2021","journal-title":"JAMA Oncol"},{"issue":"suppl 1","key":"2026042809465886900_bib19","doi-asserted-by":"crossref","first-page":"3362","DOI":"10.1182\/blood-2024-208094","article-title":"Daratumumab versus lenalidomide as maintenance therapy in newly diagnosed multiple myeloma - interim efficacy results of a randomized clinical trial","volume":"144","author":"Rajeeve","year":"2024","journal-title":"Blood"},{"key":"2026042809465886900_bib20","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.1016\/S2152-2650(24)01856-1","article-title":"Maintenance therapy cessation for multiple myeloma patients with three-year sustained MRD negative remissions","volume":"24","author":"Korde","year":"2024","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"12","key":"2026042809465886900_bib21","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1182\/bloodadvances.2016003715","article-title":"MRD detection in multiple myeloma: comparison between MSKCC 10-color single-tube and EuroFlow 8-color 2-tube methods","volume":"1","author":"Roshal","year":"2017","journal-title":"Blood Adv"},{"issue":"3","key":"2026042809465886900_bib22","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.jmoldx.2014.12.006","article-title":"Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT): a hybridization capture-based next-generation sequencing clinical assay for solid tumor molecular oncology","volume":"17","author":"Cheng","year":"2015","journal-title":"J Mol Diagn"},{"issue":"1","key":"2026042809465886900_bib23","doi-asserted-by":"crossref","first-page":"6895","DOI":"10.1038\/s41467-023-42585-9","article-title":"Enhanced clinical assessment of hematologic malignancies through routine paired tumor and normal sequencing","volume":"14","author":"Ptashkin","year":"2023","journal-title":"Nat Commun"},{"issue":"16","key":"2026042809465886900_bib24","doi-asserted-by":"crossref","first-page":"e131","DOI":"10.1093\/nar\/gkw520","article-title":"FACETS: allele-specific copy number and clonal heterogeneity analysis tool for high-throughput DNA sequencing","volume":"44","author":"Shen","year":"2016","journal-title":"Nucleic Acids Res"},{"issue":"1","key":"2026042809465886900_bib25","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1200\/JCO.23.01696","article-title":"Isatuximab, carfilzomib, lenalidomide, and dexamethasone for the treatment of high-risk newly diagnosed multiple myeloma","volume":"42","author":"Leypoldt","year":"2024","journal-title":"J Clin Oncol"},{"issue":"20","key":"2026042809465886900_bib26","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1182\/blood.2023023597","article-title":"Daratumumab, carfilzomib, lenalidomide, and dexamethasone with tandem transplant for high-risk newly diagnosed myeloma","volume":"143","author":"Touzeau","year":"2024","journal-title":"Blood"},{"issue":"21","key":"2026042809465886900_bib27","doi-asserted-by":"crossref","first-page":"532-532","DOI":"10.1182\/blood.V122.21.532.532","article-title":"Interim analysis of the Mmrf Commpass Trial, a longitudinal study in multiple myeloma relating clinical outcomes to genomic and immunophenotypic profiles","volume":"122","author":"Keats","year":"2013","journal-title":"Blood"},{"issue":"4","key":"2026042809465886900_bib28","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1056\/NEJMoa2312054","article-title":"Daratumumab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma","volume":"390","author":"Sonneveld","year":"2024","journal-title":"N Engl J Med"},{"issue":"9","key":"2026042809465886900_bib29","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1002\/ajh.27422","article-title":"Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management","volume":"99","author":"Rajkumar","year":"2024","journal-title":"Am J Hematol"},{"issue":"13","key":"2026042809465886900_bib30","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1182\/blood-2016-06-723007","article-title":"Clonal selection and double-hit events involving tumor suppressor genes underlie relapse in myeloma","volume":"128","author":"Weinhold","year":"2016","journal-title":"Blood"},{"issue":"1","key":"2026042809465886900_bib31","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1158\/2643-3230.BCD-24-0292","article-title":"Minimal residual disease as an early endpoint for accelerated drug approval in myeloma: a roadmap","volume":"6","author":"Landgren","year":"2025","journal-title":"Blood Cancer Discov"},{"key":"2026042809465886900_bib32","doi-asserted-by":"crossref","first-page":"6997","DOI":"10.1038\/ncomms7997","article-title":"APOBEC family mutational signatures are associated with poor prognosis translocations in multiple myeloma","volume":"6","author":"Walker","year":"2015","journal-title":"Nat Commun"},{"issue":"5","key":"2026042809465886900_bib33","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1038\/s41375-024-02210-0","article-title":"Redefining high risk multiple myeloma with an APOBEC\/inflammation-based classifier","volume":"38","author":"Grasedieck","year":"2024","journal-title":"Leukemia"},{"issue":"3","key":"2026042809465886900_bib34","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1158\/2643-3230.BCD-20-0132","article-title":"Revealing the impact of structural variants in multiple myeloma","volume":"1","author":"Rustad","year":"2020","journal-title":"Blood Cancer Discov"},{"issue":"11","key":"2026042809465886900_bib35","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1200\/JCO.23.01277","article-title":"Genomic classification and individualized prognosis in multiple myeloma","volume":"42","author":"Maura","year":"2024","journal-title":"J Clin Oncol"},{"issue":"3","key":"2026042809465886900_bib36","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1038\/s41375-022-01806-8","article-title":"Whole genome sequencing provides comprehensive genetic testing in childhood B-cell acute lymphoblastic leukaemia","volume":"37","author":"Ryan","year":"2023","journal-title":"Leukemia"},{"issue":"15","key":"2026042809465886900_bib37","doi-asserted-by":"crossref","first-page":"3862","DOI":"10.1182\/bloodadvances.2022008992","article-title":"Diagnostic utility of whole genome sequencing in adults with B-other acute lymphoblastic leukemia","volume":"7","author":"Leongamornlert","year":"2023","journal-title":"Blood Adv"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/8\/2616\/2513796\/blooda_adv-2025-018537-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/8\/2616\/2513796\/blooda_adv-2025-018537-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T13:47:13Z","timestamp":1777384033000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/10\/8\/2616\/566636\/IMS-IMWG-2025-consensus-genomic-staging-predicts"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,15]]},"references-count":37,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,4,28]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2025018537","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,4,28]]},"published":{"date-parts":[[2026,4,15]]}}}